Search
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Calcium glucoheptonate
go.drugbank.com/drugs/DB00326ApprovedInvestigationalCalcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.
Synonyms: calcium bis[(2ξ)-D-glycero-D-gulo-heptonate], calcium bis[(2ξ)-D-glycero-D-ido-heptonate]Fendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnIt has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalThis drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Fibrinolysin
go.drugbank.com/drugs/DB05254InvestigationalFibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da.
Synonyms: Plasmin (bos taurus)Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalDehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects.
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalCilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). … It is orally active and acts as a selective Phosphodiesterase-4 inhibitor.
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].